700 related articles for article (PubMed ID: 32216826)
1. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
2. Higher densities of tumour-infiltrating lymphocytes and CD4
Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
4. Functional CD3
Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
[TBL] [Abstract][Full Text] [Related]
5. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
[TBL] [Abstract][Full Text] [Related]
6. The immune microenvironment of breast ductal carcinoma in situ.
Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
[TBL] [Abstract][Full Text] [Related]
7. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
Kim M; Choi HY; Woo JW; Chung YR; Park SY
Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
[TBL] [Abstract][Full Text] [Related]
8. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
[TBL] [Abstract][Full Text] [Related]
9. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
Han SH; Kim M; Chung YR; Woo JW; Choi HY; Park SY
Sci Rep; 2022 Nov; 12(1):20367. PubMed ID: 36437379
[TBL] [Abstract][Full Text] [Related]
10. Relationship of the Breast Ductal Carcinoma
Hendry S; Pang JB; Byrne DJ; Lakhani SR; Cummings MC; Campbell IG; Mann GB; Gorringe KL; Fox SB
Clin Cancer Res; 2017 Sep; 23(17):5210-5217. PubMed ID: 28611201
[No Abstract] [Full Text] [Related]
11. CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ.
Morita M; Yamaguchi R; Tanaka M; Tse GM; Yamaguchi M; Kanomata N; Naito Y; Akiba J; Hattori S; Minami S; Eguchi S; Yano H
Cancer Med; 2016 Jul; 5(7):1607-18. PubMed ID: 27061242
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
[TBL] [Abstract][Full Text] [Related]
13. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.
Chen XY; Thike AA; Koh VCY; Nasir NDM; Bay BH; Tan PH
Virchows Arch; 2021 Apr; 478(4):679-686. PubMed ID: 33140128
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of S100A8-positive immune cells in relation to other immune cell infiltration in pre-invasive and invasive breast cancers.
Woo JW; Chung YR; Kim M; Choi HY; Ahn S; Park SY
Cancer Immunol Immunother; 2021 May; 70(5):1365-1378. PubMed ID: 33146829
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
Campbell MJ; Baehner F; O'Meara T; Ojukwu E; Han B; Mukhtar R; Tandon V; Endicott M; Zhu Z; Wong J; Krings G; Au A; Gray JW; Esserman L
Breast Cancer Res Treat; 2017 Jan; 161(1):17-28. PubMed ID: 27785654
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Cimino-Mathews A; Thompson E; Taube JM; Ye X; Lu Y; Meeker A; Xu H; Sharma R; Lecksell K; Cornish TC; Cuka N; Argani P; Emens LA
Hum Pathol; 2016 Jan; 47(1):52-63. PubMed ID: 26527522
[TBL] [Abstract][Full Text] [Related]
18. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
19. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
[TBL] [Abstract][Full Text] [Related]
20. Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast With Clinicopathologic Features and T-Cell Infiltration.
Kim NI; Park MH; Lee JS
Appl Immunohistochem Mol Morphol; 2020; 28(10):767-775. PubMed ID: 31714284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
